Grazoprevir is an antiviral and NS3/4A protease inhibitor used to treat hepatitis C infections. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients.
- Mechanism
- Curator reviewed
Grazoprevir is a second generation NS3/4a protease inhibitor used to inhibit viral HCV replication. NS3/4a protease is an integral part of viral replication and mediates the cleavage the virally encoded polyprotein to mature proteins (NS3, NS4A, NS4B, NS5A and NS5B). Grazoprevir inhibits the NS3/4protease enzymes of HCV genotype 1a, 1B, and 4 with IC50 values of 7pM, 4pM, and 62pM, respectively.
- Primary indication
- Grazoprevir is indicated in combination with DB11574 (as the fixed dose combination product Zepatier) with or without DB00811 for treatment of chronic HCV genotypes 1a, 1b, or 4 infection in adults.Curator reviewed · 4 structured indications
- Formula / weight
- C38H50N6O9S · 766.903 g/mol (avg)
- First approval
- Canada, 2016 · United States, 2016 · European Union, 2016
- Code names
- MK-5172
- Brand names
Resolves to
OBMNJSNZOWALQB-NCQNOWPTSA-NSMILESCOC1=CC2=NC3=C(CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)O3)C(C)(C)C)N=C2C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Grazoprevir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account